Improved survival in HPV/p16-positive oropharyngeal cancer patients treated with postoperative radiotherapy;Verbessertes Überleben von HPV/p16-positiven Oropharynxkarzinompatienten mit postoperativer Bestrahlung

Strahlentherapie und Onkologie

Volumn 191, Issue 3, 2015, Pages 209-216

  Heiduschka, Gregor ^a   Grah, Anja ^a   Oberndorfer, Felicitas ^a   Kadletz, Lorenz ^a   Altorjai, Gabriela ^a   Kornek, Gabriela ^a   Wrba, Fritz ^a   Thurnher, Dietmar ^a   Selzer, Edgar ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Carcinoma, squamous cell; Disease free survival; Head and neck cancer; Human papillomavirus; Surgery

Indexed keywords

CISPLATIN; PROTEIN P16; VIRUS DNA; VIRUS PROTEIN;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENERAL HOSPITAL; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OROPHARYNX CANCER; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RADIATION DOSE; SURVIVAL TIME; TREATMENT OUTCOME; WART VIRUS; ADJUVANT THERAPY; AGED; CARCINOMA, SQUAMOUS CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MORTALITY; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; SURVIVAL RATE; VIROLOGY;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE;

EID: 84925506945     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0753-7     Document Type: Article

References (24)

1. Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35
2. Bernier J, Cooper JS, Pajak TF et al (2005) Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 27:843–850
3. Brunner M, Koperek O, Wrba F et al (2012) HPV infection and p16 expression in carcinomas of the minor salivary glands. Eur Arch Otorhinolaryngol 269:2265–2269
4. Cooper JS, Pajak TF, Forastiere A et al (1998) Precisely defining high-risk operable head and neck tumors based on RTOG #85–03 and #88–24: targets for postoperative radiochemotherapy? Head Neck 20:588–594
5. Cooper JS, Pajak TF, Forastiere AA et al (2004) Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350:1937–1944
6. Cooper JS, Zhang Q, Pajak TF et al (2012) Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 84:1198–1205
7. Corvò R (2007) Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 85:156–170
8. Due AK, Vogelius IR, Aznar MC et al (2012) Methods for estimating the site of origin of locoregional recurrence in head and neck squamous cell carcinoma. Strahlentherapie und Onkologie 188:671–676
9. Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269
10. Forastiere A, Koch W, Trotti A, Sidransky D (2001) Head and neck cancer. N Engl J Med 345:1890–1900
11. Gillison ML, D’Souza G, Westra W et al (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407–420
12. Granata R, Miceli R, Orlandi E et al (2012) Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol 23:1832–1837
13. Heiduschka G, Grah A, Oberndorfer F et al (2014) Significance of p16 expression in head and neck cancer patients treated with radiotherapy and cetuximab. Strahlenther Onkol 190:832–838
14. Jordan RC, Lingen MW, Perez-Ordonez B et al (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36:945–954
15. Licitra L, Perrone F, Bossi P et al (2006) High-Risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 24:5630–5636
16. Lill C, Kornek G, Bachtiary B et al (2011) Survival of patients with HPV-positive oropharyngeal cancer after radiochemotherapy is significantly enhanced. Wien Klin Wochenschr 123:215–221
17. Mendenhall WM, Amdur RJ, Hinerman RW, Villaret DB, Siemann DW (2003) Postoperative radiation therapy for squamous cell carcinoma of the head and neck. Am J Otolaryngol 24:41–50
18. Mendenhall WM, Hinerman RW, Amdur RJ et al (2006) Postoperative radiotherapy for squamous cell carcinoma of the head and neck. Clin Med Res 4:200–208
19. Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJM, Brakenhoff RH (2013) Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol 49:560–566
20. Neuchrist C, Formanek M (2008) Follow up in head and neck cancer. Wien Med Wochenschr 158:273–277
21. Posner MR, Lorch JH, Goloubeva O et al (2011) Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 22:1071–1077
22. Rades D, Seibold ND, Gebhard MP, Noack F, Thorns C, Schild SE (2013) Impact of the HPV-positivity definition on the prognostic value of HPV status in patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 189:856–860
23. Seibold ND, Schild SE, Gebhard MP, Noack F, Rades D (2013) Prognosis of patients with locally advanced squamous cell carcinoma of the head and neck. Impact of tumor cell expression of EPO and EPO-R. Strahlenther Onkol 189:559–565
24. Wolff HA, Wolff CRM, Hess CF et al (2013) Secondary primary malignancies in head and neck cancer patients: high prevalence of curable-stage disease. Strahlenther Onkol 189:874–880